The estimated Net Worth of Drayton Virkler is at least $149 Tysiąc dollars as of 31 March 2023. Drayton Virkler owns over 3,990 units of Certara stock worth over $149,119 and over the last 2 years Drayton sold CERT stock worth over $0.
Drayton has made over 2 trades of the Certara stock since 2022, according to the Form 4 filled with the SEC. Most recently Drayton exercised 3,990 units of CERT stock worth $43,810 on 31 March 2023.
The largest trade Drayton's ever made was exercising 13,595 units of Certara stock on 30 September 2022 worth over $149,273. On average, Drayton trades about 5,862 units every 61 days since 2022. As of 31 March 2023 Drayton still owns at least 13,581 units of Certara stock.
You can see the complete history of Drayton Virkler stock trades at the bottom of the page.
Drayton's mailing address filed with the SEC is C/O CERTARA, INC., 100 OVERLOOK CENTER, SUITE 101, PRINCETON, NJ, 08540.
Over the last 5 years, insiders at Certara have traded over $2,048,278,243 worth of Certara stock and bought 97,245 units worth $1,908,085 . The most active insiders traders include Avatar Parent L.P.Eqt Avata..., James E Iii Cashman oraz Mason P Slaine. On average, Certara executives and independent directors trade stock every 14 days with the average trade being worth of $7,828,136. The most recent stock trade was executed by Leif E Pedersen on 9 September 2024, trading 51,224 units of CERT stock currently worth $578,319.
Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, and Australia. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Certara executives and other stock owners filed with the SEC include: